Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections
Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

NCT04628572

CompletedN/A

Sponsor: Pfizer

Conditions: Gram Negative Infections

Interventions: Ceftazidime-avibactam

Countries: India

The main objective of this non-interventional (retrospective) study is to describe the general treatment patterns, effectiveness, and safety of ceftazidime-avibactam in real-world settings in India. Eligible patients would be adults who have been treated with ≥ 48 hours of ceftazidime-avibactam in routine practice from 01 June 2019 to 01 April 2020. Data of 500 patients will be collected through the abstraction of hospital medical records (electronic) if available or through the individual patient medical record in case electronic records are not available.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

1. more than or equal to 18 years of age
2. Admitted to hospital with documented gram negative infection
3. Has received treatment for atleast 48 hours (complete) with Ceftazidime-Avibactam as a part of his routine clinical management

Exclusion Criteria:

1. The patient is enrolled in any clinical trial of an investigational product
2. Age \<18 years
3. Received Ceftazidime avibactam for less than 48 hours.
4. Patient with documented Acinetobacter infection.
5. Patient was a part of named access program or any other interventional study
Locations (8)
  • Bhandup West, India
  • Chennai, India
  • Chennai, India
  • Erandwane,, PUNE, India
  • Hyderabad, India
  • Noida, India
  • Pune, India
  • WEST Bengal, India